Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
CST-101 by CuraSen Therapeutics for Parkinson's Disease: Likelihood of Approval
CST-101 is under clinical development by CuraSen Therapeutics and currently in Phase II for Parkinson's Disease. According to GlobalData, Phase...